NCT05261191View on ClinicalTrials.gov

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

May 29, 2024

Study Completion Date

May 29, 2024

Conditions
Human Immunodeficiency Virus I InfectionImmunodeficiency Virus Type 1, HumanHuman Immunodeficiency Virus Type 1
Interventions
BIOLOGICAL

MGD020

MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

BIOLOGICAL

MGD014

MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.

Trial Locations (3)

10029

Icahn School of Medicine at Mt. Sinai, New York

27599

UNC Hospital - Chapel Hill, Chapel Hill

44106

Case Western Reserve University Hospital, Cleveland

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Department of Health and Human Services

FED

lead

MacroGenics

INDUSTRY